文献速递间质性肺疾病肺结节与肺癌

表面活性物质相关基因变异携带者肺癌高风险

High risk of lung cancer in surfactant-related gene variant carriers.
PubMed 文献 · Eur Respir J · 2024-05-02

本研究基于OrphaLung网络的横断面研究,纳入99例表面活性物质相关基因(SRG)变异成人携带者,发现20.2%合并肺癌,且风险显著高于端粒相关基因(TRG)变异携带者(亚分布风险比18.1,95%CI 7.1-44.7)。吸烟、年龄及SFTPA1/SFTPA2变异与肺癌风险相关,提示需评估定期CT随访的价值。

要点

  • SRG变异携带者肺癌发生率达20.2%,以腺癌为唯一组织学类型。
  • SRG携带者肺癌风险为TRG携带者的18.1倍(95%CI 7.1-44.7)。
  • 吸烟(OR 20.7)和SFTPA1/SFTPA2变异(OR 3.97)与肺癌风险独立相关。

核心结论

  • SRG变异携带者肺癌风险高,带来特定的筛查、诊断和治疗挑战。
  • 应评估定期CT扫描随访的获益。

研究设计与样本

  • 横断面研究,纳入OrphaLung网络全部成人SRG变异携带者,并与TRG变异携带者比较肺癌风险。
  • SRG变异携带者99例(SFTPA1 18例、SFTPA2 31例、SFTPC 24例、ABCA3 14例、NKX2-1 12例),TRG变异携带者233例。

主要发现

  • SRG携带者中20例(20.2%)患肺癌,各基因分布:SFTPA1 7例、SFTPA2 8例、SFTPC 3例、NKX2-1 2例、ABCA3 0例。
  • 肺癌风险与年龄(OR 1.04,95%CI 1.01-1.08)、吸烟(OR 20.7,95%CI 6.60-76.2)及SFTPA1/SFTPA2变异(OR 3.97,95%CI 1.39-13.2)相关。
  • 腺癌为唯一报告的组织学类型,3份样本肿瘤细胞PD-L1表达≥1%。
  • 分期:局限期(I/II)8例(40%),局部晚期(III)2例(10%),转移性(IV)10例(50%)。
  • 中位总生存期24个月,I/II期生存更优;未发现适合靶向治疗的体细胞变异。

关键数值与推荐

  • SRG携带者肺癌风险 vs TRG携带者的亚分布风险比为18.1(95%CI 7.1-44.7)。
  • 肺癌风险与年龄OR 1.04(95%CI 1.01-1.08)、吸烟OR 20.7(95%CI 6.60-76.2)、SFTPA1/SFTPA2变异OR 3.97(95%CI 1.39-13.2)相关。

临床怎么用

  • 对SRG变异携带者应重视肺癌筛查,尤其吸烟者及SFTPA1/SFTPA2变异者。
  • 诊断时注意腺癌可能,并根据分期和体能状态选择手术、系统治疗或最佳支持治疗。
  • 定期CT随访的获益尚需前瞻性评估。

局限性

  • 横断面设计无法确定因果关系。
  • 样本量有限(SRG携带者99例)。
  • 随访与筛查数据未详细报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers. METHODS: We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers. RESULTS: We identified 99 SRG adult variant carriers (SFTPA1 (n=18), SFTPA2 (n=31), SFTPC (n=24), ABCA3 (n=14) and NKX2-1 (n=12)), including 20 (20.2%) with lung cancer (SFTPA1 (n=7), SFTPA2 (n=8), SFTPC (n=3), NKX2-1 (n=2) and ABCA3 (n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01-1.08), smoking (OR 20.7, 95% CI 6.60-76.2) and SFTPA1/SFTPA2 variants (OR 3.97, 95% CI 1.39-13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patients versus TRG patients was 18.1 (95% CI 7.1-44.7). CONCLUSIONS: The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Brudon A, Legendre M, Mageau A, et al. High risk of lung cancer in surfactant-related gene variant carriers. Eur Respir J. 2024. PMID: 38575158. doi:10.1183/13993003.01809-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。